These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37759620)

  • 1. Characterization of the Intracellular Acidity Regulation of Brain Tumor Cells and Consequences for Therapeutic Optimization of Temozolomide.
    Tafech A; Jacquet P; Beaujean C; Fertin A; Usson Y; Stéphanou A
    Biology (Basel); 2023 Sep; 12(9):. PubMed ID: 37759620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the Importance of Acidity in Cancer Cells and Therapy.
    Tafech A; Stéphanou A
    Biology (Basel); 2024 Mar; 13(4):. PubMed ID: 38666837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulating tumor acidification as a cancer treatment strategy.
    McCarty MF; Whitaker J
    Altern Med Rev; 2010 Sep; 15(3):264-72. PubMed ID: 21155627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor acidity: From hallmark of cancer to target of treatment.
    Bogdanov A; Bogdanov A; Chubenko V; Volkov N; Moiseenko F; Moiseyenko V
    Front Oncol; 2022; 12():979154. PubMed ID: 36106097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.
    Musah-Eroje A; Watson S
    J Neurooncol; 2019 Apr; 142(2):231-240. PubMed ID: 30694423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
    Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
    Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRC8A potentiates temozolomide sensitivity in glioma cells via activating mitochondria-dependent apoptotic pathway.
    Yang C; He L; Chen G; Ning Z; Xia Z
    Hum Cell; 2019 Jan; 32(1):41-50. PubMed ID: 30426452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
    Mousavi SM; Hosseindoost S; Mahdian SMA; Vousooghi N; Rajabi A; Jafari A; Ostadian A; Hamblin MR; Hadjighassem M; Mirzaei H
    Pathol Res Pract; 2023 May; 245():154427. PubMed ID: 37028110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance.
    Motaln H; Koren A; Gruden K; Ramšak Ž; Schichor C; Lah TT
    Oncotarget; 2015 Dec; 6(38):40998-1017. PubMed ID: 26517510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor acidity, chemoresistance and proton pump inhibitors.
    De Milito A; Fais S
    Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
    Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
    Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
    Xu K; Zhang Z; Pei H; Wang H; Li L; Xia Q
    Oncol Rep; 2017 Apr; 37(4):2391-2397. PubMed ID: 28260024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
    Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
    Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
    Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
    Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
    Brunetti A; Marinelli O; Morelli MB; Iannarelli R; Amantini C; Russotti D; Santoni G; Maggi F; Nabissi M
    Phytomedicine; 2019 Jan; 52():51-59. PubMed ID: 30599912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
    Wang X; Chen JX; Liu YH; You C; Mao Q
    Neurol Sci; 2013 Aug; 34(8):1421-8. PubMed ID: 23224642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
    Moroz MA; Huang R; Kochetkov T; Shi W; Thaler H; de Stanchina E; Gamez I; Ryan RP; Blasberg RG
    Clin Cancer Res; 2011 May; 17(10):3282-92. PubMed ID: 21385926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
    Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.